Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05425459 · ClinicalTrials.gov registry record · NA
RESPONDER-HF Trial
A NA study of Heart Failure and Heart Failure, Diastolic, sponsored by Corvia Medical.
- Active
- Registry status
- NA
- Development phase
- 750
- Enrollment target
- 20
- Study locations
NCT05425459: Active NA study of Heart Failure and Heart Failure, Diastolic, sponsored by Corvia Medical.
NCT05425459 is a NA study of Heart Failure and Heart Failure, Diastolic that is active but no longer recruiting, run by Corvia Medical. The registered enrollment target is 750 participants, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05425459, a NA study of Heart Failure and Heart Failure, Diastolic, is active but no longer recruiting, sponsored by Corvia Medical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 750 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization
Primary Outcome
The primary endpoint is a composite of heart failure event rates and Kansas City Cardiomyopathy Questionnaire (KCCQ) at 12 months. Responses are given on a Likert scale that for each individual item is scored on a scale of 0-100 with higher scores indicating better health.
Conditions Studied
Interventions
- DEVICE Corvia Atrial Shunt System / IASD System II
- OTHER Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
Study Locations (20)
Florida
- Memorial Regional Hospital - Hollywood
- NCH Naples - Naples
- Cleveland Clinic Florida - Weston
Illinois
- Northwestern University - Chicago
- University of Chicago Medical Center - Chicago
- Endeavor Health-Northshore - Glenview
California
- Scripps Clinic - La Jolla
- MemorialCare Long Beach Medical Center - Long Beach
Georgia
- Northside Hospital Gwinnett Campus - Lawrenceville
- Wellstar Kennestone - Marietta
Massachusetts
- Lahey Hospital & Medical Center - Burlington
- UMass Memorial Hospital University Campus - Worcester
Arizona
- Arizona Cardiovascular Research Center - Phoenix
Delaware
- Christiana Care Health Services - Newark
Louisiana
- LSU Health Shreveport - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2022-11-17 |
| Est. Completion | 2031-03 |
| Phase | NA |
What the registry record for NCT05425459 still lists
NCT05425459 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Corvia Atrial Shunt System / IASD System II is the first listed.
NCT05425459 names 20 study sites across 13 states, led by Florida, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT05425459 about?
NCT05425459 is a clinical study titled "RESPONDER-HF Trial". Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization
What is the current status of trial NCT05425459?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 750 participants. The study started on 2022-11-17. Estimated completion is 2031-03.
What conditions does trial NCT05425459 study?
This clinical trial studies the following conditions: Heart Failure, Heart Failure, Diastolic.
What interventions are being tested in trial NCT05425459?
The interventions under investigation include: Corvia Atrial Shunt System / IASD System II (DEVICE), Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) (OTHER).
Who is sponsoring clinical trial NCT05425459?
This trial is sponsored by Corvia Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05425459 being conducted?
This trial has 20 study locations across Arizona, California, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05425459's enrollment target sits among peer trials
750 83rd of 397 higher than 315 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI